Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.

Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Nevanlinna H.

Int J Cancer. 2019 Nov 15;145(10):2692-2700. doi: 10.1002/ijc.32309. Epub 2019 Apr 25.

2.

Correction to: Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells.

Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A.

BMC Cancer. 2019 Jan 14;19(1):57. doi: 10.1186/s12885-018-5234-4.

3.

Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.

Luhtala S, Staff S, Kallioniemi A, Tanner M, Isola J.

BMC Cancer. 2018 Oct 26;18(1):1045. doi: 10.1186/s12885-018-4917-1.

4.

Wound healing of human embryonic stem cell-derived retinal pigment epithelial cells is affected by maturation stage.

Abu Khamidakh AE, Rodriguez-Martinez A, Kaarniranta K, Kallioniemi A, Skottman H, Hyttinen J, Juuti-Uusitalo K.

Biomed Eng Online. 2018 Jul 31;17(1):102. doi: 10.1186/s12938-018-0535-z.

5.

Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells.

Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A.

BMC Cancer. 2018 Mar 27;18(1):325. doi: 10.1186/s12885-018-4261-5. Erratum in: BMC Cancer. 2019 Jan 14;19(1):57.

6.

Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro.

Kuittinen T, Rovio P, Staff S, Luukkaala T, Kallioniemi A, Grénman S, Laurila M, Mäenpää J.

Anticancer Res. 2017 Dec;37(12):6575-6581.

PMID:
29187432
7.

Transcription factors-Intricate players of the bone morphogenetic protein signaling pathway.

Ampuja M, Kallioniemi A.

Genes Chromosomes Cancer. 2018 Jan;57(1):3-11. doi: 10.1002/gcc.22502. Epub 2017 Sep 27. Review.

PMID:
28857319
8.

Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.

Määttä KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, Laasanen SL, Schleutker J.

BMC Cancer. 2017 Jul 24;17(1):496. doi: 10.1186/s12885-017-3488-x.

9.

FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.

Kiiski JI, Tervasmäki A, Pelttari LM, Khan S, Mantere T, Pylkäs K, Mannermaa A, Tengström M, Kvist A, Borg Å, Kosma VM, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Winqvist R, Nevanlinna H.

Breast Cancer Res Treat. 2017 Nov;166(1):217-226. doi: 10.1007/s10549-017-4388-0. Epub 2017 Jul 12.

10.

PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells.

Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, Pantel K, Kronqvist P, Kallioniemi O, Carpèn O, Iljin K.

J Pathol Clin Res. 2017 Apr 4;3(2):123-138. doi: 10.1002/cjp2.69. eCollection 2017 Apr.

11.

Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility.

Mantere T, Tervasmäki A, Nurmi A, Rapakko K, Kauppila S, Tang J, Schleutker J, Kallioniemi A, Hartikainen JM, Mannermaa A, Nieminen P, Hanhisalo R, Lehto S, Suvanto M, Grip M, Jukkola-Vuorinen A, Tengström M, Auvinen P, Kvist A, Borg Å, Blomqvist C, Aittomäki K, Greenberg RA, Winqvist R, Nevanlinna H, Pylkäs K.

Sci Rep. 2017 Apr 6;7(1):681. doi: 10.1038/s41598-017-00766-9.

12.

Integrated RNA-seq and DNase-seq analyses identify phenotype-specific BMP4 signaling in breast cancer.

Ampuja M, Rantapero T, Rodriguez-Martinez A, Palmroth M, Alarmo EL, Nykter M, Kallioniemi A.

BMC Genomics. 2017 Jan 11;18(1):68. doi: 10.1186/s12864-016-3428-1.

13.

Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth.

Vuorinen EM, Rajala NK, Rauhala HE, Nurminen AT, Hytönen VP, Kallioniemi A.

Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):211-219. doi: 10.1016/j.bbadis.2016.09.015. Epub 2016 Sep 21.

14.

FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.

Kiiski JI, Fagerholm R, Tervasmäki A, Pelttari LM, Khan S, Jamshidi M, Mantere T, Pylkäs K, Bartek J, Bartkova J, Mannermaa A, Tengström M, Kosma VM, Winqvist R, Kallioniemi A, Aittomäki K, Blomqvist C, Nevanlinna H.

Int J Cancer. 2016 Dec 15;139(12):2760-2770. doi: 10.1002/ijc.30394. Epub 2016 Sep 19.

15.

RAD51B in Familial Breast Cancer.

Pelttari LM, Khan S, Vuorela M, Kiiski JI, Vilske S, Nevanlinna V, Ranta S, Schleutker J, Winqvist R, Kallioniemi A, Dörk T, Bogdanova NV, Figueroa J, Pharoah PD, Schmidt MK, Dunning AM, García-Closas M, Bolla MK, Dennis J, Michailidou K, Wang Q, Hopper JL, Southey MC, Rosenberg EH, Fasching PA, Beckmann MW, Peto J, Dos-Santos-Silva I, Sawyer EJ, Tomlinson I, Burwinkel B, Surowy H, Guénel P, Truong T, Bojesen SE, Nordestgaard BG, Benitez J, González-Neira A, Neuhausen SL, Anton-Culver H, Brenner H, Arndt V, Meindl A, Schmutzler RK, Brauch H, Brüning T, Lindblom A, Margolin S, Mannermaa A, Hartikainen JM, Chenevix-Trench G; kConFab/AOCS Investigators, Van Dyck L, Janssen H, Chang-Claude J, Rudolph A, Radice P, Peterlongo P, Hallberg E, Olson JE, Giles GG, Milne RL, Haiman CA, Schumacher F, Simard J, Dumont M, Kristensen V, Borresen-Dale AL, Zheng W, Beeghly-Fadiel A, Grip M, Andrulis IL, Glendon G, Devilee P, Seynaeve C, Hooning MJ, Collée M, Cox A, Cross SS, Shah M, Luben RN, Hamann U, Torres D, Jakubowska A, Lubinski J, Couch FJ, Yannoukakos D, Orr N, Swerdlow A, Darabi H, Li J, Czene K, Hall P, Easton DF, Mattson J, Blomqvist C, Aittomäki K, Nevanlinna H.

PLoS One. 2016 May 5;11(5):e0153788. doi: 10.1371/journal.pone.0153788. eCollection 2016.

16.

The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model.

Ampuja M, Alarmo EL, Owens P, Havunen R, Gorska AE, Moses HL, Kallioniemi A.

Cancer Lett. 2016 Jun 1;375(2):238-244. doi: 10.1016/j.canlet.2016.03.008. Epub 2016 Mar 9.

PMID:
26970275
17.

Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion.

Alarmo EL, Havunen R, Häyrynen S, Penkki S, Ketolainen J, Nykter M, Kallioniemi A.

Genes Chromosomes Cancer. 2016 Mar;55(3):227-36. doi: 10.1002/gcc.22324. Epub 2015 Dec 18.

PMID:
26684238
18.

Effects of Cytokine Activation and Oxidative Stress on the Function of the Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells.

Juuti-Uusitalo K, Nieminen M, Treumer F, Ampuja M, Kallioniemi A, Klettner A, Skottman H.

Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6265-74. doi: 10.1167/iovs.15-17333. Erratum in: Invest Ophthalmol Vis Sci. 2018 May 1;59(6):2263.

PMID:
26431480
19.

Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.

Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, Shimelis H, Vilske S, Kallioniemi A, Schleutker J, Leminen A, Bützow R, Blomqvist C, Barkardottir RB, Couch FJ, Aittomäki K, Nevanlinna H.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15172-7. doi: 10.1073/pnas.1407909111. Epub 2014 Oct 6.

20.

Breast-cancer risk in families with mutations in PALB2.

Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M.

N Engl J Med. 2014 Aug 7;371(6):497-506. doi: 10.1056/NEJMoa1400382.

21.

Finnish Fanconi anemia mutations and hereditary predisposition to breast and prostate cancer.

Mantere T, Haanpää M, Hanenberg H, Schleutker J, Kallioniemi A, Kähkönen M, Parto K, Avela K, Aittomäki K, von Koskull H, Hartikainen JM, Kosma VM, Laasanen SL, Mannermaa A, Pylkäs K, Winqvist R.

Clin Genet. 2015 Jul;88(1):68-73. doi: 10.1111/cge.12447. Epub 2014 Jul 30.

PMID:
24989076
22.

Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients.

Wikman H, Westphal L, Schmid F, Pollari S, Kropidlowski J, Sielaff-Frimpong B, Glatzel M, Matschke J, Westphal M, Iljin K, Huhtala H, Terracciano L, Kallioniemi A, Sauter G, Müller V, Witzel I, Lamszus K, Kemming D, Pantel K.

Oncotarget. 2014 May 30;5(10):3076-87.

23.

Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families.

Heikkinen T, Khan S, Huovari E, Vilske S, Schleutker J, Kallioniemi A, Blomqvist C, Aittomäki K, Nevanlinna H.

Breast Cancer Res Treat. 2014 Apr;144(2):437-41. doi: 10.1007/s10549-014-2884-z. Epub 2014 Feb 22.

PMID:
24562772
24.

KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells in vitro.

Laurila E, Vuorinen E, Savinainen K, Rauhala H, Kallioniemi A.

Exp Cell Res. 2014 Mar 10;322(1):159-67. doi: 10.1016/j.yexcr.2013.11.014. Epub 2013 Nov 23.

PMID:
24275456
25.

BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment.

Ampuja M, Jokimäki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo EL, Kallioniemi A.

BMC Cancer. 2013 Sep 22;13:429. doi: 10.1186/1471-2407-13-429.

26.

The diverse role of miR-31 in regulating cancer associated phenotypes.

Laurila EM, Kallioniemi A.

Genes Chromosomes Cancer. 2013 Dec;52(12):1103-13. doi: 10.1002/gcc.22107. Epub 2013 Sep 2. Review.

PMID:
23999990
27.

The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients.

Korhonen T, Kuukasjärvi T, Huhtala H, Alarmo EL, Holli K, Kallioniemi A, Pylkkänen L.

Breast. 2013 Dec;22(6):1119-24. doi: 10.1016/j.breast.2013.06.001. Epub 2013 Jul 14.

28.

The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues.

Laurila R, Parkkila S, Isola J, Kallioniemi A, Alarmo EL.

Int J Clin Exp Pathol. 2013 Jun 15;6(7):1400-8. Print 2013.

29.

HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.

Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, Laasanen SL, Kallioniemi A, Nevanlinna H, Aaltonen L, Vessella RL, Auvinen A, Visakorpi T, Tammela TL, Schleutker J.

Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):452-60. doi: 10.1158/1055-9965.EPI-12-1000-T. Epub 2013 Jan 4.

30.

Silencing of the ARP2/3 complex disturbs pancreatic cancer cell migration.

Rauhala HE, Teppo S, Niemelä S, Kallioniemi A.

Anticancer Res. 2013 Jan;33(1):45-52.

PMID:
23267127
31.

Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development.

Alarmo EL, Huhtala H, Korhonen T, Pylkkänen L, Holli K, Kuukasjärvi T, Parkkila S, Kallioniemi A.

Mod Pathol. 2013 Jan;26(1):10-21. doi: 10.1038/modpathol.2012.128. Epub 2012 Aug 17.

32.

Bone morphogenetic protein 4-a fascinating regulator of cancer cell behavior.

Kallioniemi A.

Cancer Genet. 2012 Jun;205(6):267-77. doi: 10.1016/j.cancergen.2012.05.009. Review.

PMID:
22749032
33.

Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network.

Pylkäs K, Vuorela M, Otsukka M, Kallioniemi A, Jukkola-Vuorinen A, Winqvist R.

PLoS Genet. 2012;8(6):e1002734. doi: 10.1371/journal.pgen.1002734. Epub 2012 Jun 21.

34.

A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.

Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, Aaltonen LA, Leminen A, Heikkilä P, Blomqvist C, Bützow R, Aittomäki K, Nevanlinna H.

J Med Genet. 2012 Jul;49(7):429-32. doi: 10.1136/jmedgenet-2012-100852. Epub 2012 May 31.

35.

Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions.

Solyom S, Aressy B, Pylkäs K, Patterson-Fortin J, Hartikainen JM, Kallioniemi A, Kauppila S, Nikkilä J, Kosma VM, Mannermaa A, Greenberg RA, Winqvist R.

Sci Transl Med. 2012 Feb 22;4(122):122ra23. doi: 10.1126/scitranslmed.3003223.

36.

Both inhibition and enhanced expression of miR-31 lead to reduced migration and invasion of pancreatic cancer cells.

Laurila EM, Sandström S, Rantanen LM, Autio R, Kallioniemi A.

Genes Chromosomes Cancer. 2012 Jun;51(6):557-68. doi: 10.1002/gcc.21941. Epub 2012 Feb 16.

PMID:
22344632
37.

Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes.

Rodriguez-Martinez A, Alarmo EL, Saarinen L, Ketolainen J, Nousiainen K, Hautaniemi S, Kallioniemi A.

BMC Med Genomics. 2011 Nov 25;4:80. doi: 10.1186/1755-8794-4-80.

38.

Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins.

Kallio H, Tolvanen M, Jänis J, Pan PW, Laurila E, Kallioniemi A, Kilpinen S, Tuominen VJ, Isola J, Valjakka J, Pastorekova S, Pastorek J, Parkkila S.

PLoS One. 2011;6(11):e27152. doi: 10.1371/journal.pone.0027152. Epub 2011 Nov 7.

39.

Bone morphogenetic protein -4 and -5 in pancreatic cancer--novel bidirectional players.

Virtanen S, Alarmo EL, Sandström S, Ampuja M, Kallioniemi A.

Exp Cell Res. 2011 Sep 10;317(15):2136-46. doi: 10.1016/j.yexcr.2011.06.001. Epub 2011 Jun 17.

PMID:
21704030
40.

The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.

Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM, Zhu T, Sukumar S.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2736-41. doi: 10.1073/pnas.1018859108. Epub 2011 Jun 20.

41.

RAD51C is a susceptibility gene for ovarian cancer.

Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K, Bützow R, Nevanlinna H.

Hum Mol Genet. 2011 Aug 15;20(16):3278-88. doi: 10.1093/hmg/ddr229. Epub 2011 May 25.

PMID:
21616938
42.

MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer.

Kuuselo R, Savinainen K, Sandström S, Autio R, Kallioniemi A.

Int J Cancer. 2011 Dec 1;129(11):2553-65. doi: 10.1002/ijc.25924. Epub 2011 Mar 25.

43.

DNA copy number analysis on tissue microarrays.

Kallioniemi A.

Methods Mol Biol. 2010;664:127-34. doi: 10.1007/978-1-60761-806-5_13.

PMID:
20690059
44.

Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.

Wolf M, Korja M, Karhu R, Edgren H, Kilpinen S, Ojala K, Mousses S, Kallioniemi A, Haapasalo H.

BMC Cancer. 2010 May 5;10:181. doi: 10.1186/1471-2407-10-181.

45.

Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?

Alarmo EL, Kallioniemi A.

Endocr Relat Cancer. 2010 Apr 21;17(2):R123-39. doi: 10.1677/ERC-09-0273. Print 2010 Jun. Review.

PMID:
20335308
46.

19q13 amplification is associated with high grade and stage in pancreatic cancer.

Kuuselo R, Simon R, Karhu R, Tennstedt P, Marx AH, Izbicki JR, Yekebas E, Sauter G, Kallioniemi A.

Genes Chromosomes Cancer. 2010 Jun;49(6):569-75. doi: 10.1002/gcc.20767.

47.

Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4.

Ketolainen JM, Alarmo EL, Tuominen VJ, Kallioniemi A.

Breast Cancer Res Treat. 2010 Nov;124(2):377-86. doi: 10.1007/s10549-010-0808-0. Epub 2010 Feb 25.

PMID:
20182795
48.

Characterization of the 7q21-q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer.

Laurila E, Savinainen K, Kuuselo R, Karhu R, Kallioniemi A.

Genes Chromosomes Cancer. 2009 Apr;48(4):330-9. doi: 10.1002/gcc.20643.

PMID:
19145645
49.

BMP7 influences proliferation, migration, and invasion of breast cancer cells.

Alarmo EL, Pärssinen J, Ketolainen JM, Savinainen K, Karhu R, Kallioniemi A.

Cancer Lett. 2009 Mar 8;275(1):35-43. doi: 10.1016/j.canlet.2008.09.028. Epub 2008 Nov 5.

PMID:
18980801
50.

Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.

Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, Monni O.

BMC Genomics. 2008 Jul 24;9:348. doi: 10.1186/1471-2164-9-348.

Supplemental Content

Loading ...
Support Center